ESMO 2017 | Is molecular imaging the best way to determine response to treatment?

Suzanne Louise Topalian

Suzanne Louise Topalian, MD, from the Johns Hopkins Medical Institute, Baltimore, MD, discusses how to determine response to treatment at the European Society for Medical Oncology (ESMO) 2017 in Madrid, Spain. The difference between a complete response to treatment and partial tumor regression can be unclear. This can be because what can appear to be tumor tissue in a CT scan can simply be scar tissue or inflammatory infiltrate, suggesting that patient survival may be the most important endpoint of the efficacy of treatment.

Share this video